Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

A trial drug has kept Desiree Dufour's breast cancer at bay — and now, the medication has been approved by the FDA. She has ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Reseachers from WEHI (Melbourne, Australia) have found a new way to predict a subset of patients who are likely to become ...

In a small subset of those patients, the combination resulted in a strong response with tumor shrinkage and no disease ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Researchers at the University of Virginia have discovered a new mechanism driving drug resistance in pancreatic ductal ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

University of Iowa researchers have landed a $10-million federal grant to develop a new treatment for ovarian cancer. Jill ...